Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in Louisiana
13 open options
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 159 sites
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 212 sites
- TRIALPHASE2 / PHASE3RECRUITING
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACP-204 · Placebo — 148 sites
- TRIALNARECRUITING
Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI)
Physical activity program · Successful Aging — 1 site
- TRIALPHASE3RECRUITING
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Donanemab · Placebo — 59 sites
- TRIALNARECRUITING
Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"
Physical activity · Successful Aging — 1 site
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
KarXT · Placebo — 154 sites
- TRIALPHASE2RECRUITING
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
LHP588 · LHP588 · Placebo Drug — 40 sites
- TRIALPHASE2RECRUITING
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
BMS-986368 · Placebo — 75 sites
- TRIALPHASE3RECRUITING
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 143 sites
- TRIALNARECRUITING
Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition
Physiological Insulin Intervention — 1 site
- TRIALPHASE3RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
KarXT — 429 sites
- TRIALPHASE2RECRUITING
Clinical Trial on Agitation in Alzheimer's Dementia
IGC-AD1-Active · IGC-AD1-Placebo — 31 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.